Pharma News

India’s largest pharmaceutical company, Sun Pharmaceutical Industries has reported robust financial results for the financial year ended March 31, 2026, while also announcing a final dividend of ₹5 per equity share for shareholders.

Glenmark Pharmaceuticals announced that its US-based subsidiary, Glenmark Pharmaceuticals Inc., USA, has agreed to settle long-running antitrust litigation in the United States related to alleged price-fixing and anti-competitive practices in the generic drug market.

According to the company’s regulatory filing submitted to the stock exchanges, Glenmark USA will pay a total settlement amount of 29.628 million USD in annual instalments over five years. The settlement is still subject to approval by the court overseeing the litigation.

In a major breakthrough for liver disease treatment, Gilead Sciences has received accelerated approval from the U.S. FDA for Hepcludex (bulevirtide-gmod), making it the first and only approved therapy for chronic Hepatitis Delta Virus (HDV) infection in the United States.

The U.S. Food and Drug Administration approved Hepcludex (bulevirtide-gmod) injection to treat chronic hepatitis delta virus (HDV) infection in adults without cirrhosis (advanced liver scarring) or with compensated cirrhosis. Bulevirtide is the first FDA-approved treatment for chronic HDV infection, a serious and life-threatening condition that can cause rapid development of liver fibrosis (scarring), liver cancer, liver failure, and even death.

Gilead Sciences and the World Health Organization have expanded their long-standing partnership to accelerate the elimination of visceral leishmaniasis (VL), also known as kala-azar, one of the world’s deadliest parasitic diseases.

Venus Remedies has achieved a major milestone after receiving Marketing Authorization from the Saudi Food and Drug Authority for its specialty oncology therapy Plerixafor. The approval marks the company’s first-ever global authorization for the drug and strengthens its growing focus on complex injectable therapies in regulated international markets.

Dr. Reddy’s Laboratories has announced the launch of Obeda® tablets, an oral semaglutide therapy for patients with diabetes in India. The launch marks another major step in the company’s expansion of its GLP-1 portfolio after recently introducing semaglutide injections in India and Canada.